Observational studyBMC cardiovascular disorders2026
Real-world outcomes of Left Atrial Appendage Occlusion with the Amplatzer™ Amulet™: a multicentre observational registry from Southeast Asia.
Observational study in BMC cardiovascular disorders, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundLeft Atrial Appendage Occlusion (LAAO) is an alternative therapy for atrial fibrillation (AF) patients at high risk of stroke who have contraindications to long term oral anticoagulation (OAC). However, real-world data specifically regarding the Amplatzer™ Amulet™ device remains limited in Southeast Asian (SEA) populations. This study evaluated the procedural characteristics, safety profiles and 1-year clinical outcomes of the Amulet™ device in the multi-country SEA cohort.
methodsThis was a multicentre observational study included four centres across three SEA countries (Malaysia, Indonesia and Thailand) from February 2019 to January 2024. The primary outcome was a composite of cardiac mortality and ischemic stroke at 1 year.
resultsA total of 104 patients were enrolled. The mean age was 67.2 ± 10.1 years old and 67.3% male. The mean CHA2DS2-VASc was 4.02 ± 1.45 and mean HAS-BLED score was 3.11 ± 1.17. Majority of the patients (64.4%) had ≥ 2 indications for LAAO implantation. Main indications for LAAO implantation were HAS-BLED score ≥ 3 (55.8%), contraindication for OAC because of renal failure (41.3%) and contraindication for OAC because of bleeding (24.0%). Intracardiac echocardiogram was used in 19.3% of the procedure. The periprocedural complications rate was 2.9%. Device implantation was successful in 98.1%, and 77.9% was successful at first deployment. The 1-year all-cause mortality was 10.6%, with 2.9% cardiac related mortality. Risk of recurrent stroke at 1-year was 1.9% with 1 (1%) major bleeding event. At 12-month, 83.5% of the patients were on single or no antiplatelet therapy.
conclusionsPatients from SEA had multiple indications for LAAO. Overall, the dual-seal Amulet™ device demonstrated high procedural success, low complication rates and associated with low rate of AF-related thromboembolic event while using single antiplatelet therapy in most of the patients. (280 words)
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.